BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.

Netcracker Technology, a wholly-owned subsidiary of NEC Corporation, has the expertise, culture and resources to help service providers around the world transform their businesses to thrive in the digital economy. Our innovative solutions, value-driven services and unbroken delivery track record have enabled our customers to grow and succeed for more than three decades. With the latest technological advancements in key areas including 5G monetization, AI, automation and vertical industries, we help service providers to reach their transformation goals, advance their telco to techco evolution and realize business growth and profitability. To learn more, visit www.netcracker.com.